SCHEDULE 13G/A: RGM Capital, LLC Discloses 6.5% Stake in Avanos Medical, Inc.

RGM Capital, LLC has filed an amended Schedule 13G, reporting a 6.5% beneficial ownership stake in Avanos Medical, Inc. as of December 31, 2024.

Summary

• RGM Capital, LLC, a Delaware-based investment adviser, reported beneficial ownership of 2,986,519 shares of Avanos Medical, Inc. common stock.
• This ownership represents 6.5% of the total outstanding class of Avanos Medical, Inc. securities.
• RGM Capital, LLC holds shared voting power and shared dispositive power over all 2,986,519 beneficially owned shares.
• The filing is an Amendment No. 3 to a previously filed Schedule 13G, indicating an update to an existing position.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Avanos Medical, Inc.

Sentiment

Score: 5

Explanation: A Schedule 13G is a neutral, factual disclosure of beneficial ownership. It does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook, but rather the investment position of a reporting entity.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in Avanos Medical, Inc., a company operating in the medical device sector. Such disclosures are common for investment advisers managing client assets and reflect their portfolio allocations within the healthcare industry. It provides transparency on a notable investor's position in the company.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity.

Key Dates

Keywords

Avanos Medical Inc., RGM Capital LLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Medical Devices, Healthcare